Abstract: A portable urine collection system (200) may include a urine collection device, a conduit (217) in fluid communication with the urine collection device (212), a urine collection container (214) having an interior region, a pump (216), and a container support (202). The pump is in fluid communication with the urine collection container and is configured to pull a vacuum on the interior region of the urine collection container effective to draw urine from the urine collection device through the conduit into the urine collection container. The container support is configured to detachably secure to a wheelchair and support at least the urine collection container.

Abstract: Methods for treating coronavirus disease 2019 (COVID-19), the disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections, is described. The methods can be used to reduce the severity of outcomes related to COVID-19, such as hospitalization and ventilation. For example, treatment of a subject with a therapeutic agent that neutralizes interleukin 13 (IL-13) can result in reduced risk for mechanical ventilation in the subject. Also described are methods of predicting risk of mechanical ventilation in subjects with COVID-19.

Abstract: Lighting assemblies for interiors of vehicles, interior panels for interiors of vehicles, and vehicles are provided herein. In one example, the lighting assembly includes a backing structure having a first backing surface configured to face the interior when the lighting assembly is mounted in the vehicle. A bezel comprises a wall that extends from an outer edge portion to an inner edge portion. The inner edge portion is spaced apart from the first backing surface to define a gap and surrounds an opening that is configured to expose at least a portion of the first backing surface to the interior. A light source is disposed between the backing structure and the bezel and is covered by the wall. The light source is operative to produce light that passes from the light source through the gap onto the first backing surface and is reflected therefrom through the opening to the interior.

Abstract: An adjustable tie rod includes a first end defined by a screw rod, wherein the screw rod includes a threaded portion, and a second end opposite the first end, wherein an overall length of the adjustable tie rod is defined as a distance between the first end and the second end along a longitudinal axis of the adjustable tie rod. A tie rod shaft extends between and couples the first end and the second end, and a gearbox is fixed with respect to the tie rod shaft. An adjustment actuator is operatively coupled to the gearbox such that selective actuation of the adjustment actuator causes translation of the screw rod along the longitudinal axis and with respect to the gearbox when the first end is prevented from rotating about the longitudinal axis, thereby adjusting the overall length of the adjustable tie rod.

Abstract: This invention relates to carbapenem compounds of the following formula: wherein A, Z, X, R1, and R4 are as described herein, as well as stereoisomers, pharmaceutically acceptable salts or N-oxides thereof, which may be useful for the treatment of bacterial infections, particularly drug-resistant bacterial infections, as well as the processes for the preparation of compounds, the pharmaceutical compositions of these compounds and their use in the treatment of bacterial infection.

Abstract: Lighting assemblies for interiors of vehicles, interior panels for interiors of vehicles, and vehicles are provided herein. In one example, the lighting assembly includes a backing structure having a first backing surface configured to face the interior when the lighting assembly is mounted in the vehicle. A bezel comprises a wall that extends from an outer edge portion to an inner edge portion. The inner edge portion is spaced apart from the first backing surface to define a gap and surrounds an opening that is configured to expose at least a portion of the first backing surface to the interior. A light source is disposed between the backing structure and the bezel and is covered by the wall. The light source is operative to produce light that passes from the light source through the gap onto the first backing surface and is reflected therefrom through the opening to the interior.

Abstract: The present invention relates to oxazolidinone compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, E, and R1 are as defined herein. The present invention also relates to compositions which comprise at least one oxazolidinone compound of the invention. The invention also provides methods for inhibiting growth of mycobacterial cells as well as a method of treating mycobacterial infections by Mycobacterium tuberculosis comprising administering a therapeutically effective amount of an oxazolidinone of the invention and/or a pharmaceutically acceptable salt thereof, or a composition comprising such compound and/or salt.

Abstract: An adjustable tie rod includes a first end defined by a screw rod, wherein the screw rod includes a threaded portion, and a second end opposite the first end, wherein an overall length of the adjustable tie rod is defined as a distance between the first end and the second end along a longitudinal axis of the adjustable tie rod. A tie rod shaft extends between and couples the first end and the second end, and a gearbox is fixed with respect to the tie rod shaft. An adjustment actuator is operatively coupled to the gearbox such that selective actuation of the adjustment actuator causes translation of the screw rod along the longitudinal axis and with respect to the gearbox when the first end is prevented from rotating about the longitudinal axis, thereby adjusting the overall length of the adjustable tie rod.

Abstract: The present invention relates to oxazolidinone compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, E, and R1 are as defined herein. The present invention also relates to compositions which comprise at least one oxazolidinone compound of the invention. The invention also provides methods for inhibiting growth of mycobacterial cells as well as a method of treating mycobacterial infections by Mycobacterium tuberculosis comprising administering a therapeutically effective amount of an oxazolidinone of the invention and/or a pharmaceutically acceptable salt thereof, or a composition comprising such compound and/or salt.

Abstract: An interior panel for an aircraft, an aircraft including an interior panel, and a method for making an interior panel for an aircraft are provided. In one example, the interior panel includes a support substrate that has a substrate surface. A first trim section is coupled to the support substrate. The first trim section has a first exposed surface that extends to a first edge portion. A second trim section is coupled to the support substrate. The second trim section has a second exposed surface that extends to a second edge portion that is disposed adjacent to the first edge portion. The first edge portion is offset from the second edge portion to define a gap. A light source is substantially covered by the first exposed surface and generates light that passes through the gap and illuminates at least a portion of the second exposed surface.

Abstract: This invention relates to carbapenem compounds, their stereoisomers, pharmaceutically acceptable salts or N-oxides thereof, which may be useful for the treatment of bacterial infections, particularly drug-resistant bacterial infections, as well as the processes for the preparation of compounds, the pharmaceutical compositions of these compounds and their use in the treatment of bacterial infection.

Abstract: The present invention relates to metallo-?-lactamase inhibitor compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein Z, RA, X1, X2 and R1 are as defined herein. The present invention also relates to compositions which comprise a metallo-?-lactamase inhibitor compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, optionally in combination with a beta lactam antibiotic and/or a beta-lactamase inhibitor. The invention further relates to methods for treating a bacterial infection comprising administering to a patient a therapeutically effective amount of a compound of the invention, in combination with a therapeutically effective amount of one or more ?-lactam antibiotics and optionally in combination with one or more beta-lactamase inhibitor compounds. The compounds of the invention are useful in the methods described herein for overcoming antibiotic resistance.

Abstract: The present invention relates to oxazolidinone compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, E, and R1 are as defined herein. The present invention also relates to compositions which comprise at least one oxazolidinone compound of the invention. The invention also provides methods for inhibiting growth of mycobacterial cells as well as a method of treating mycobacterial infections by Mycobacterium tuberculosis comprising administering a therapeutically effective amount of an oxazolidinone of the invention and/or a pharmaceutically acceptable salt thereof, or a composition comprising such compound and/or salt.

Abstract: The present invention relates to metallo-?-lactamase inhibitor compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein Z, RA, X1, X2 and R1 are as defined herein. The present invention also relates to compositions which comprise a metallo-?-lactamase inhibitor compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, optionally in combination with a beta lactam antibiotic and/or a beta-lactamase inhibitor. The invention further relates to methods for treating a bacterial infection comprising administering to a patient a therapeutically effective amount of a compound of the invention, in combination with a therapeutically effective amount of one or more ?-lactam antibiotics and optionally in combination with one or more beta-lactamase inhibitor compounds. The compounds of the invention are useful in the methods described herein for overcoming antibiotic resistance.

Abstract: The present invention relates to metallo-?-lactamase inhibitor compounds of Formula I: (I) and pharmaceutically acceptable salts thereof, wherein Z, RA, X1, X2 and RB are as defined herein. The present invention also relates to compositions which comprise a metallo-?-lactamase inhibitor compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, optionally in combination with a beta lactam antibiotic and/or a beta-lactamase inhibitor. The invention further relates to methods for treating a bacterial infection comprising administering to a patient a therapeutically effective amount of a compound of the invention, in combination with a therapeutically effective amount of one or more ?-lactam antibiotics and optionally in combination with one or more beta-lactamase inhibitor compounds. The compounds of the invention are useful in the methods described herein for overcoming antibiotic resistance.

Abstract: The present invention relates to metallo-beta-lactamase inhibitor compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein Z, RA, X1, X2 and R1 are as defined herein. The present invention also relates to compositions which comprise a metallo-beta-lactamase inhibitor compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, optionally in combination with a beta-lactam antibiotic and/or a beta-lactamase inhibitor. The invention further relates to methods for treating a bacterial infection comprising administering to a patient a therapeutically effective amount of a compound of the invention, in combination with a therapeutically effective amount of one or more ?-lactam antibiotics and optionally in combination with one or more beta-lactamase inhibitor compounds. The compounds of the invention are useful in the methods described herein for overcoming antibiotic resistance.

Abstract: The present invention relates to novel nargenicin related compounds which can inhibit DnaE and have antibacterial, particularly antimycobacterial activity against Mycobacterium tuberculosis. The present invention also relates to method for inhibiting growth of mycobacterial cells as well as a method of treating mycobacterial infections by Mycobacterium tuberculosis by administering an antimycobacterially effective amount of nargenicin or a nargenicin-related compound and/or their pharmaceutically acceptable salts.